Vaccination is crucial to avoid getting Covid-19. Now, will it be enough? The new variants put all this at risk and it is also possible that new ones will come out. Then and according to the Spanish scientist Vicente Lárraga, the pandemic could lengthen three years, but we would already be in a stage of normality much earlier.
In an interview with EFE Salud, the professional, who also leads one of the three CSIC groups for the development of the Spanish vaccine against COVID-19, explains that normality could be in Spain in autumn.
Still, he thinks that the pandemic will not go away, as other experts have predicted and will continue with us for two or three years. This is why he believes it is important to continue researching on vaccines and their development.
How is the Spanish vaccine?
There are different prototypes, so we could have several vaccines produced and developed in the country. The one Vicente Lárraga works on is somewhat similar to Pfizer and Moderna, but can be stored at room temperature, unlike the previous ones, which need a really much superior cold preservation.
And if new variants come out, the Spanish vaccine can be quickly remade to adapt to these. And so the pandemic does not last three years.
Now they are in more trials, and in the interview with EFE Salud, the expert clarifies that it is possible that the preclinical phase ends this summer and then they will go to the clinical phase if they receive the pertinent permits.
As in Spain the vaccination process is accelerated, on the dates determined by Lárraga for the clinical phase there will be few infected people and for this reason the vaccine will have to be tested in other countries that have a greater incidence in Covid-19 with more incidence.
Spanish intranasal vaccine
Developed by the National Center for Biotechnology (CNB-CSIC), this vaccine, with 100% immunity, will prevent vaccinated people from getting sick or transmitting the virus.
Several dates are being considered, although at first it was said that could be ready by early 2022, now from the CSIC they point out that it could be available at the end of next year.
Virologist Luis Enjuanes and his team, who are developing this intranasal vaccine, explain to La Sexta that it has 100% effectiveness, a total immunity in which you can neither catch nor transmit the virus.
It should be noted that it is intranasal, and it will not be inoculated with a puncture in the arm, if not directly in the nose, thus it acts through the entry route of the virus. The doctor commented that this helps the vaccine go to various areas such as the lungs.